Panzem NCD + Temozolomide
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Glioblastoma Multiforme
Conditions
Recurrent Glioblastoma Multiforme
Trial Timeline
Apr 1, 2007 → Oct 1, 2008
NCT ID
NCT00481455About Panzem NCD + Temozolomide
Panzem NCD + Temozolomide is a phase 2 stage product being developed by CASI Pharmaceuticals for Recurrent Glioblastoma Multiforme. The current trial status is completed. This product is registered under clinical trial identifier NCT00481455. Target conditions include Recurrent Glioblastoma Multiforme.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00481455 | Phase 2 | Completed |
Competing Products
20 competing products in Recurrent Glioblastoma Multiforme